FDA Waxman/Hatch Fix Proposal Is “Beefed-Up” Patent Declarations
Executive Summary
FDA is considering requiring innovator companies to provide more information about patents they file for listing in the "Orange Book" as one remedy to Waxman/Hatch loopholes
You may also be interested in...
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation